Speaker(s): 

Moderator(s): 

Learning Objectives: 

At the conclusion of this session, the participant should be able to: 

• Distinguish atrial fibrillation with RVR that is driving hemodynamic compromise from AF that is a compensatory response to acute illness, and select rate-control strategy accordingly.
• Apply the ARISTOTLE-derived apixaban dose-reduction criteria correctly, and explain why off-label dose reduction is associated with worse outcomes rather than safer ones.
• Evaluate high-grade AV block for reversible causes before referral, and differentiate nodal from infranodal block on the surface ECG.
• Determine the appropriate inpatient workup for asymptomatic non-sustained VT and incidental telemetry findings, including when echocardiography, ambulatory monitoring, or cardiac MRI is indicated.
• Review, Risk-stratify syncope using history, ECG, and validated tools, and identify the testing that current guidelines designate as low-yield.
• Specify the clinical findings that warrant electrophysiology consultation, and describe what conduction system pacing offers over conventional right ventricular pacing.

Disclosure of Relevant Financial Relationships with/without Commercial Interests:

The Planning Committee consisting of Connor Dougherty, DO, Karlyn Paglia, MD, Juan R. Escobar, MD, Melad Kamel, MD, Shashank Kotakonda, MD, Jayalakshmi Nair, MD, Jignesh Patel, MD, Jameson Woodard, MD, Hasan Zerti, MD, Robert Yanoshak, DO, and Habib Hamoud, MD have no identified disclosures. 

CE Committee Member/Content Reviewers have nothing to disclose. 

Any/All relevant financial relationships have been mitigated. 

Content Disclosure: 

This presentation/content is HIPAA compliant. 

Commercial Support for this Session

None.